Skip to main content
Clinical Trials/NCT03734484
NCT03734484WithdrawnPhase 2

Gram Type Infection-Specific Sepsis Identification Using Machine Learning

Dascena0 sitesStarted: May 1, 2022Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Withdrawn
Sponsor
Primary Endpoint
Change in time to antibiotic administration

Study Overview

Brief Summary

The focus of this study will be to conduct a prospective, randomized controlled trial (RCT) at Cape Regional Medical Center (CRMC), Oroville Hospital (OH), and UCSF Medical Center (UCSF) in which a Gram type infection-specific algorithm will be applied to EHR data for the detection of severe sepsis. For patients determined to have a high risk of severe sepsis, the algorithm will generate automated voice, telephone notification to nursing staff at CRMC, OH, and UCSF. The algorithm's performance will be measured by analysis of the primary endpoint, time to antibiotic administration. The secondary endpoint will be reduction in the administration of unnecessary antibiotics, which includes reductions in secondary antibiotics and reductions in total time on antibiotics.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Diagnostic
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • All adults above age 18 who are a member of one of the three subpopulations studied in this trial (patients with Gram-positive infection, patients with Gram-negative infection, and patients with mixed Gram-positive and Gram-negative infection) are eligible to participate in the study.

Exclusion Criteria

  • Under age 18
  • No record of Gram infection

Outcomes

Primary Outcomes

Change in time to antibiotic administration

Time Frame: Through study completion, an average of 8 months

Change in time period between diagnosis of Gram infection and administration of antibiotics to treat infection

Secondary Outcomes

  • Change in administration of unnecessary antibiotics(Through study completion, an average of 8 months)

Investigators

Sponsor
Dascena
Sponsor Class
Industry
Responsible Party
Sponsor

Similar Trials